Insight

Unmet needs, uncommon commitment: The shift toward investment in rare diseases

Unmet needs, uncommon commitment: The shift toward investment in rare diseases

Join biotech leaders, emerging innovators, investors and patient advocacy group reps for a candid, interactive and enlightening discussion about rare disease drug discovery and development.

POLs: Patient opinion leaders emerge as key to success in orphan drug designation

POLs: Patient opinion leaders emerge as key to success in orphan drug designation


Mar 27, 2017

Orphan drugs are wicked hot. Wall Street loves them. And patients are a powerful force that can make or break a decision to grant that...

Biotechs successfully navigate alternative paths to financing

Biotechs successfully navigate alternative paths to financing


Mar 27, 2017

Project awards, strategic venture funds and now crowd-funding offer alternatives to traditional venture funds for emerging biotech companies. Pfizer's new strategic fund or the well-established...

partnering360®: leverage and cultivate your dealmaker network

partnering360 is the network for dealmakers in the life science industry. This global community of more than 38,000 is constantly growing, and the partnering opportunities continually updating.